5-Fluorouridine
Based on 9 publication(s) in Google Scholar
5-Fluorouridine, a metabolite of5-Fluorouracil (HY-90006), is a potent ribozyme self-cleavage inhibitor. 5-Fluorouridine incorporates into both total and poly A RNA and has antiproliferative activity. 5-Fluorouridine induces apoptosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.97%
- CAS No.: 316-46-1
- Formule: C9H11FN2O6
- Masse moléculaire:262.19
-
Stockage:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Nucleotide Compound Library
HY-L044
-
Drug Metabolite Library
HY-L098
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Chemotherapy Drug Library
HY-L112
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) 5-Fluorouridine
More- Nat Metab. 2025 Nov 13. [Abstract]
- Nat Plants. 2025 Sep 12. [Abstract]
- Nano Lett. 2023 Oct 25;23(20):9437-9444. [Abstract]
- Cell Rep. 2025 Jan 13;44(1):115179. [Abstract]
- Precis Clin Med. 2026 Mar 14;9(2):pbag009. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- Virology. 2024 Sep 12:600:110237. [Abstract]
- bioRxiv. 2025 Sep 22.
- bioRxiv. 2025 Mar 13:2025.03.11.642569. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
1.9 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.
Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.
|
10.1016/0960-894X(96)00339-3 |
| AZ-521 cell line | IC50 |
0.05 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of AZ-521 tumor cell line from stomach.
Compound was tested for its inhibitory effect on the growth of AZ-521 tumor cell line from stomach.
|
10.1016/0960-894X(96)00339-3 |
| CCRF-CEM | IC50 |
5.0 x 10-8 M
Compound: 2
|
Concentration required for the 50% inhibition of growth of CCRF-CEM human leukemia cells in culture
Concentration required for the 50% inhibition of growth of CCRF-CEM human leukemia cells in culture
|
[PMID: 7120290] |
| COLO 320DM | IC50 |
0.0054 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of COLO 320DM tumor cell line from colon.
Compound was tested for its inhibitory effect on the growth of COLO 320DM tumor cell line from colon.
|
10.1016/0960-894X(96)00339-3 |
| DLD-1 | IC50 |
0.073 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of DLD-1 tumor cell line from colon.
Compound was tested for its inhibitory effect on the growth of DLD-1 tumor cell line from colon.
|
10.1016/0960-894X(96)00339-3 |
| FM3A | IC50 |
0.014 μM
Compound: 5-FUrd
|
Cytostatic activity against mouse FM3A cells after 2 days by coulter counting analysis
Cytostatic activity against mouse FM3A cells after 2 days by coulter counting analysis
|
[PMID: 21330014] |
| HCT-15 | IC50 |
0.047 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of HCT-15 tumor cell line from colon.
Compound was tested for its inhibitory effect on the growth of HCT-15 tumor cell line from colon.
|
10.1016/0960-894X(96)00339-3 |
| HeLa | IC50 |
0.016 μM
Compound: 5-FUrd
|
Cytostatic activity against human HeLa cells in presence of 500 uM uracil
Cytostatic activity against human HeLa cells in presence of 500 uM uracil
|
[PMID: 21330014] |
| HeLa | IC50 |
0.017 μM
Compound: 5-FUrd
|
Cytostatic activity against human HeLa cells in presence of 20 uM thymidine
Cytostatic activity against human HeLa cells in presence of 20 uM thymidine
|
[PMID: 21330014] |
| HeLa | IC50 |
0.022 μM
Compound: 5-FUrd
|
Cytostatic activity against human HeLa cells in presence of 20 uM 2'-deoxyuridine
Cytostatic activity against human HeLa cells in presence of 20 uM 2'-deoxyuridine
|
[PMID: 21330014] |
| HeLa | IC50 |
1.6 μM
Compound: 5-FUrd
|
Cytostatic activity against human HeLa cells in presence of 500 uM uridine
Cytostatic activity against human HeLa cells in presence of 500 uM uridine
|
[PMID: 21330014] |
| HT-1080 | IC50 |
0.041 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of HT1080 sarcoma tumor cell line.
Compound was tested for its inhibitory effect on the growth of HT1080 sarcoma tumor cell line.
|
10.1016/0960-894X(96)00339-3 |
| IM-9 | IC50 |
<0.01 μg/mL
Compound: 5-F-Urd
|
In vitro antitumor activity in IM-9 cell lines
In vitro antitumor activity in IM-9 cell lines
|
[PMID: 8648611] |
| K562 | IC50 |
0.026 μg/mL
Compound: 5-F-Urd
|
In vitro antitumor activity in K-562 cell lines
In vitro antitumor activity in K-562 cell lines
|
[PMID: 8648611] |
| KKLS | IC50 |
0.016 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of KKLS tumor cell line from stomach.
Compound was tested for its inhibitory effect on the growth of KKLS tumor cell line from stomach.
|
10.1016/0960-894X(96)00339-3 |
| L1210 | IC50 |
0.0075 μM
Compound: 5-FUrd
|
Cytostatic activity against mouse L1210 cells in presence of 500 uM uracil
Cytostatic activity against mouse L1210 cells in presence of 500 uM uracil
|
[PMID: 21330014] |
| L1210 | IC50 |
0.014 μM
Compound: 5-FUrd
|
Cytostatic activity against mouse L1210 cells after 2 days by coulter counting analysis
Cytostatic activity against mouse L1210 cells after 2 days by coulter counting analysis
|
[PMID: 21330014] |
| L1210 | IC50 |
0.026 μM
Compound: 5-FUrd
|
Cytostatic activity against mouse L1210 cells in presence of 20 uM 2'-deoxyuridine
Cytostatic activity against mouse L1210 cells in presence of 20 uM 2'-deoxyuridine
|
[PMID: 21330014] |
| L1210 | IC50 |
0.72 μM
Compound: 5-FUrd
|
Cytostatic activity against mouse L1210 cells in presence of 500 uM uridine
Cytostatic activity against mouse L1210 cells in presence of 500 uM uridine
|
[PMID: 21330014] |
| L1210 | IC50 |
1.2 μM
Compound: 5-FUrd
|
Cytostatic activity against mouse L1210 cells in presence of 20 uM thymidine
Cytostatic activity against mouse L1210 cells in presence of 20 uM thymidine
|
[PMID: 21330014] |
| L1210 | IC50 |
>10-4 M
Compound: 5-FdUrd
|
Inhibition of L1210 leukemic cell growth in mice 1 hr after exposure to 5*10e-8 M of compound
Inhibition of L1210 leukemic cell growth in mice 1 hr after exposure to 5*10e-8 M of compound
|
[PMID: 2704026] |
| L1210 | IC50 |
3 nM
Compound: 5-FdUrd
|
In vitro inhibitory growth activity against L1210 leukemic cells by incubating 5 x 10E4 cells/mL for 48 hour in 2 mL of media.
In vitro inhibitory growth activity against L1210 leukemic cells by incubating 5 x 10E4 cells/mL for 48 hour in 2 mL of media.
|
[PMID: 2704026] |
| L1210 | IC50 |
3 x 10-9 M
Compound: 5-FdUrd
|
In vitro inhibitory growth activity against L1210 leukemic cells by incubating 5 x 10E4 cells/mL for 48 hour in 2 mL of media.
In vitro inhibitory growth activity against L1210 leukemic cells by incubating 5 x 10E4 cells/mL for 48 hour in 2 mL of media.
|
[PMID: 2704026] |
| L1210 | IC50 |
5.0 x 10-9 M
Compound: 2
|
Concentration required for the 50% inhibition of growth of L1210 mouse leukemia cells in culture
Concentration required for the 50% inhibition of growth of L1210 mouse leukemia cells in culture
|
[PMID: 7120290] |
| MKN-28 | IC50 |
0.028 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of MKN-28 tumor cell line from stomach.
Compound was tested for its inhibitory effect on the growth of MKN-28 tumor cell line from stomach.
|
10.1016/0960-894X(96)00339-3 |
| MKN-45 | IC50 |
0.026 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of MKN-45 tumor cell line from stomach.
Compound was tested for its inhibitory effect on the growth of MKN-45 tumor cell line from stomach.
|
10.1016/0960-894X(96)00339-3 |
| MOLT-3 | IC50 |
<0.01 μg/mL
Compound: 5-F-Urd
|
In vitro antitumor activity in MOLT-3 cell lines
In vitro antitumor activity in MOLT-3 cell lines
|
[PMID: 8648611] |
| NUGC-3 | IC50 |
0.022 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of NUGC-3 tumor cell line from stomach.
Compound was tested for its inhibitory effect on the growth of NUGC-3 tumor cell line from stomach.
|
10.1016/0960-894X(96)00339-3 |
| PANC-1 | IC50 |
11 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of PANC-1 tumor cell line from pancreas.
Compound was tested for its inhibitory effect on the growth of PANC-1 tumor cell line from pancreas.
|
10.1016/0960-894X(96)00339-3 |
| PHA-Ly | IC50 |
<0.1 μg/mL
Compound: 5-F-Urd
|
IIn vitro antitumor activity in PHA-Ly cell lines
IIn vitro antitumor activity in PHA-Ly cell lines
|
[PMID: 8648611] |
| SNU-C2A | IC50 |
0.045 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of SUN-C2A tumor cell line from colon.
Compound was tested for its inhibitory effect on the growth of SUN-C2A tumor cell line from colon.
|
10.1016/0960-894X(96)00339-3 |
| SW48 | IC50 |
0.016 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of SW-48 tumor cell line from colon.
Compound was tested for its inhibitory effect on the growth of SW-48 tumor cell line from colon.
|
10.1016/0960-894X(96)00339-3 |
| T-24 | IC50 |
0.014 μM
Compound: FUrd (5-fluorouridine)
|
Compound was tested for its inhibitory effect on the growth of T24 tumor cell line from bladder.
Compound was tested for its inhibitory effect on the growth of T24 tumor cell line from bladder.
|
10.1016/0960-894X(96)00339-3 |
| U-937 | IC50 |
<0.01 μg/mL
Compound: 5-F-Urd
|
In vitro antitumor activity in U-937 cell lines
In vitro antitumor activity in U-937 cell lines
|
[PMID: 8648611] |
5-Fluorouridine (167 μM; 24-96 h) inhibits MKN45 cells and MKN28 cells in a time-dependent manner[1].
5-Fluorouridine (10 μM; 24 h; HCT-116 cells) induces apoptosis and increases the percentage of apoptotic cells. 5-Fluorouridine upregulates the expression of 33 genes, including a group of genes as growth factors, cytokines and chemokines (e.g. IL-3, IL -4, B-cell growth factor 1 and stem cell growth factor)[2].
5-Fluorouridine (10 μM; 8-24 h; HCT-116 cells) incorporates into both total and poly A RNA[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male CBA/J mice (17-20 g; 6-8 weeks of age)[3]
-
Dosage:Intraperitoneal injection; daily, 20 days
-
Administration:567, 700, 900, 1100, 1300, and 1500 mg/kg
-
Result:567, 700, 900, 1100, 1300, and 1500 mg/kg
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 316-46-1
-
Appearance Solid
-
Masse moléculaire 262.19
-
Formule C9H11FN2O6
-
Color White to off-white
-
SMILES
OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(C(F)=C2)=O)=O)O1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Metab
Uridine-sensitized screening identifies demethoxy-coenzyme Q and NUDT5 as regulators of nucleotide synthesis. [Abstract]2025 Nov 13. PMID: 41233602 -
Nat Plants
An apoplastic fungal effector disrupts N-glycosylation of ZmLecRK1, inducing its degradation to suppress disease resistance in maize. [Abstract]2025 Sep 12. PMID: 40940425 -
Nano Lett
2023 Oct 25;23(20):9437-9444. PMID: 37818841 -
Cell Rep
mTORC1 regulates the pyrimidine salvage pathway by controlling UCK2 turnover via the CTLH-WDR26 E3 ligase. [Abstract]2025 Jan 13;44(1):115179. PMID: 39808525
5-Fluorouridine purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Jan 13;44(1):115179. [Abstract]
Cell survival at 72 h after treatment with 5-azacytidine (5-AzaCd) or 5-fluorouridine (5-FUd, 0-100 μM) with or without dTAGv1 (100 nM) in HCT116 UCK2-FKBP12F36V K/I cells. dTAGv1-mediated degradation of UCK2 results in 156-fold resistance to 5-FUd and 1.6-fold to 5-AzaCd. Mean ± SD, n = 12 biological replicates.
-
Precis Clin Med
Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3. [Abstract]2026 Mar 14;9(2):pbag009. PMID: 41978696 -
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
Virology
5-Bromo-2'-deoxyuridine inhibits African swine fever virus (ASFV) replication via interfering viral DNA replication and suppressing the formation of viral factories. [Abstract]2024 Sep 12:600:110237. PMID: 39288610 -
-
bioRxiv
Uridine-sensitized screening identifies genes and metabolic regulators of nucleotide synthesis. [Abstract]2025 Mar 13:2025.03.11.642569. PMID: 40161720
Solvant et solubilité
DMSO : ≥ 100 mg/mL (381.40 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 100 mg/mL (381.40 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 110 mg/mL (419.54 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Wu FL, et, al. Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2'-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics. Cancer Lett. 2015 Jul 10;363(1):7-16. [Content Brief]
[2]. Schmittgen TD, et, al. Diverse gene expression pattern during 5-fluorouridine-induced apoptosis. Int J Oncol. 2005 Aug;27(2):297-306. [Content Brief]
[3]. Houghton JA, et, al. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res. 1979 Jul;39(7 Pt 1):2406-13. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 3.8140 mL | 19.0701 mL | 38.1403 mL | 95.3507 mL |
| 5 mM | 0.7628 mL | 3.8140 mL | 7.6281 mL | 19.0701 mL | |
| 10 mM | 0.3814 mL | 1.9070 mL | 3.8140 mL | 9.5351 mL | |
| 15 mM | 0.2543 mL | 1.2713 mL | 2.5427 mL | 6.3567 mL | |
| 20 mM | 0.1907 mL | 0.9535 mL | 1.9070 mL | 4.7675 mL | |
| 25 mM | 0.1526 mL | 0.7628 mL | 1.5256 mL | 3.8140 mL | |
| 30 mM | 0.1271 mL | 0.6357 mL | 1.2713 mL | 3.1784 mL | |
| 40 mM | 0.0954 mL | 0.4768 mL | 0.9535 mL | 2.3838 mL | |
| 50 mM | 0.0763 mL | 0.3814 mL | 0.7628 mL | 1.9070 mL | |
| 60 mM | 0.0636 mL | 0.3178 mL | 0.6357 mL | 1.5892 mL | |
| 80 mM | 0.0477 mL | 0.2384 mL | 0.4768 mL | 1.1919 mL | |
| 100 mM | 0.0381 mL | 0.1907 mL | 0.3814 mL | 0.9535 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
5-Fluorouridine Related Classifications
HY-107856 Related Classifications
Powered by Bioz